title: [Cycloplatam in the treatment of patients with disseminated prostatic cancer].
abstract: A 22% response rate was achieved in clinical trials of Russian drug cycloplatam in disseminated and hormone-resistant cancer of the prostate. In 80% of cases the drug has improved quality of life of patients with prostatic cancer stage III and IV. Antitumor effect and low toxicity make cycloplatam applicable in combined therapy of prostatic cancer.
authors.forename: B P
authors.initials: BP
authors.lastname: Matveev
authors.forename: V A
authors.initials: VA
authors.lastname: Gorbunova
authors.forename: N B
authors.initials: NB
authors.lastname: Smirnova
authors.forename: Zh D
authors.initials: ZhD
authors.lastname: Zhumagazin
authors.forename: B V
authors.initials: BV
authors.lastname: Bukharkin
authors.forename: N F
authors.initials: NF
authors.lastname: Orel
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C055928:cycloplatam